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Molecular geneticof mutations in the LRRK2 gene redeﬁne the role of genetic susceptibility in
Parkinson's disease. Dominant missense mutations that fulﬁll initial criteria for potential gain of function
mechanisms coupled with enzymatic activity likely amenable to small molecule inhibition position LRRK2 as
a promising therapeutic target. Herein, key observations from the clinic to the test tube are highlighted
together with points of contention and outstanding critical issues. Resolution of the critical issues will
expedite the development of therapies that exploit LRRK2 activity for neuroprotection strategies.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionParkinson's disease (PD) encompasses a myriad of symptoms
traditionally deﬁned by prominent movement related dysfunction
initially alleviated through dopamine modiﬁcation therapies, in
addition to non-motor symptoms unresponsive to L-dopa treatment
[1]. Recent advances in a pathological understanding of the disease
conﬁrm the association of a massive loss of dopaminergic neurome-
lanin-positive neurons in the substantia nigra pars compacta with the
movement disorder phenotype, in conjunction with α-synuclein
positive lesions throughout many regions of the brain before and
after degeneration in the midbrain [2]. As the most common
movement disorder, PD is a major cause of morbidity and mortality
and therapies that modify the progressive nature of the disease
remain unidentiﬁed. Molecular genetic studies in the last decade
provide clues to the underlying pathogenic mechanisms and potential
targets for therapeutic intervention.
The identiﬁcation of autosomal-dominant mutations in the leu-
cine-rich repeat kinase 2 gene (LRRK2) in a signiﬁcant proportion of
cases in some populations redeﬁne the role of genetic susceptibility in
PD. As opposed to mutations in the α-synuclein gene (PARK1 and
PARK4) rarely found in PD cases and parkin (PARK2) mutations
common in early onset PD, LRRK2 (PARK8)-linked PD cases more
closely associate with the expected phenotype of typical late-onset
PD. Moreover, genetic alterations, namely missense mutations, within+1 205 996 6580.
ll rights reserved.LRRK2 that concede to minimum reasonable criteria for disease
causality suggest gain-of-function mechanisms potentially amenable
to therapeutic intervention. As a protein kinase, LRRK2 belongs to a
class of proteins successfully targeted by small molecule inhibitors in
the treatment of human disease. Coupling gain-of-function disease
associated activity with a protein theoretically modiﬁable by small
molecules, LRRK2 represents a strong target for the development of
therapies that slow or halt disease progress. This review dedicates
towards highlighting key observations related to LRRK2, questions
that need resolution, and suggestions for moving forward.
2. Genetic aspects of LRRK2 and PD
The PARK8 locus was initially described in a large Japanese kindred
[3]. Soon after, association of the locus on chromosome 12 was
replicated in two large and eight smaller additional kindreds,
suggesting that association of the PARK8 locus with PD spans
ethnicities and might be a more common cause of PD than previously
characterized PARK loci [4]. The reﬁned PARK8 locus includes 29
annotated and putative genes on chromosome 12 comprehended of
13Mbp. To identify the disease-associated gene within PARK8, the
regionwas divided to conquer; the smallest genes sequenced ﬁrst and
corresponding mRNA transcripts analyzed for expression. After
several misleading sidetracks typical for positional cloning projects,
the last of the annotated genes waited on the list, a gene that only had
an anonymous and hostile index consisting of more than 30
incompletely annotated exons. An amino acid exchange in the
predicted exon 31 was followed by the discovery of another non-
Table 1
Variations within LRRK2
Variant Region
Within
LRRK2
Evidence for
Pathogenicity
Kinase
activity
GTPase
activity
Ref
In vitro In vitro
E10K N-Term Conservation medium n.d. n.d. [74]
A211V N-Term Conservation medium n.d. n.d. [75]
E334K N-Term Conservation medium n.d. n.d. [74]
K544V N-Term Conservation medium n.d. n.d. [75]
M712V N-Term Conservation medium n.d. n.d. [76]
R793M N-Term Conservation medium n.d. n.d. [77]
Q930R N-Term Conservation medium n.d. n.d. [77]
S973N N-Term Conservation medium n.d. n.d. [78]
R1067Q LRR Conservation medium n.d. n.d. [79]
S1096C LRR Conservation medium n.d. n.d. [77]
Q1111H LRR Conservation medium n.d. n.d. [74]
L1114L LRR Segregating n.d. n.d. [4]
L1122V LRR No conservation increased n.d. [4,41]
A1151T LRR Conservation medium n.d. n.d. [80]
L1165P LRR Conservation medium n.d. n.d. [81]
I1192V LRR Conservation medium n.d. n.d. [74]
S1228T LRR Conservation medium n.d. n.d. [77]
R1325Q GTPase Conservation medium n.d. n.d. [82]
I1371V GTPase Conservation medium No change n.d. [41,83]
R1441C/G/H GTPase Conservation high increased/
unaltered
decreased [4,5,22,
46,48,84]Segregating
K1468E GTPase Conservation medium n.d. n.d. [82]
R1483Q GTPase Conservation medium n.d. n.d. [82]
R1514Q COR Conservation medium increased n.d. [41,85]
P1542S COR Conservation medium n.d. n.d. [85]
V1613A COR Conservation medium n.d. n.d. [86]
R1628P COR Conservation medium n.d. n.d. [85]
Y1699C COR Conservation high increased/
unaltered
n.d. [4,5,41,
44,46]Segregating
R1728L,H COR Conservation medium n.d. n.d. [76]
L1795F COR Conservation high n.d. n.d. [74]
M1869T/V Kinase Conservation medium n.d. n.d. [8,85]
1874Stop Kinase Conservation medium n.d. n.d. [8]
R1941H Kinase Conservation medium decreased/
unaltered
n.d. [44,46,87]
Y2006H Kinase Conservation medium n.d. n.d. [88]
I2012T Kinase Conservation medium decreased n.d. [4,41,
44,46]
G2019S Kinase Conservation high increased n.d. [8–10,41,
59,70]Segregating
Drosophila model
Mouse model
I2020T Kinase Conservation high increased/
decreased/
unaltered
n.d. [4,41,
44–46]Segregating
T2031S Kinase Conservation medium n.d. n.d. [88]
N2081D Kinase Conservation medium n.d. n.d. [82]
T2141M C-Term No conservation n.d. n.d. [76]
R2143H C-Term No conservation n.d. n.d. [76]
Y2189C C-Term Conservation medium n.d. n.d. [82]
T2356I C-Term No conservation unaltered n.d. [46,87]
G2385R C-Term Conservation medium unaltered/
decreased
n.d. [41,46,85]
V2390M C-Term Conservation medium n.d. n.d. [89]
M2397T C-Term Conservation medium n.d. n.d. [85]
L2466H C-Term Conservation medium n.d. n.d. [76]
Known pathogenic variations are shown in bold. Known polymorphisms that are
frequently found in controls are not included. (n.d. not determined).
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predicted exon. Since these variants segregated with disease in the
families and initial sequencing of two-thousand control chromosomes
failed to identify the variants, the alterations themselves were likely
the disease causing mutations underlying PARK8. Thus, a common
world-spanning effort that took several years of dedicated work
resulted in the unambiguous identiﬁcation of the gene in PARK8
responsible for PD [4,5].
Finding an appropriate name for the corresponding PARK8 gene
was the ﬁrst step. Upon searching the databases it became clear that
the unruly gene containing the PD-linked mutations belongs to the
ROCO family of proteins, an in silico predicted group of molecules
deﬁned by the Ras of Complex (ROC) GTPase-like domain adjacent to a
C-terminal of ROC (COR) linker [6]. Additionally, a kinase domainwith
similar amino acid composition to MAPKKK (mitogen activated
protein kinase kinase kinase) is often present in ROCO proteins
together with other regulatory and protein-interaction domains.
Unique to the PARK8 gene is sequence encoding an almost one-
thousand amino acid long N-terminus with little homology to any
other mammalian protein. Humans have two ROCO family proteins
and since human ROCO1 was previously annotated with little
consideration towards functionality as leucine-rich repeat kinase 1,
the PD-linked gene in PARK8 had no chance besides leucine-rich repeat
kinase 2 (LRRK2, pronounced lurk-two or lark-two). Besides the
leucine-rich repeat domain in LRRK2, other potential interaction
domains include an WD-40 like domain near the C-terminus and N-
terminal repeat structures and some Ankyrin-repeat like sequences, in
addition to a Rab-like GTPase domain, all of which arbitrarily
neglected from the LRRK2 gene nomenclature. In addition, the
implication of LRRK2 as a kinase despite functional validation could
have made the initial LRRK2 designation both inaccurate and
misleading, since conserved kinase domains in proteins that are not
authentic kinases have been described [7].
At the same time as the R1441C (Exon 31) and the Y1699C (Exon
35) mutation in LRRK2 were linked with PD in one family from
Western Nebraskawith probable English origin and in one family from
Canada, US, France and Germany with German origin [4], Paisan-Ruiz
et al. [5] reported R1441G in four Basque families and Y1699C in one
English family and dubbed the protein product of LRRK2 dardarin after
the Basque word dardara, meaning tremor. DiFonzo, Gilks and Nichols
with coworkers went on to describe the G2019S mutation [8–10],
recognized as the most frequently found LRRK2 mutation that spans
diverse ethnicities. Finally, the LRRK2 gene in the Japanese kindred
responsible for the original identiﬁcation of the PARK8 locus was
sequenced and the I2020T mutation identiﬁed [11]. All four sites
(R1441, Y1699, G2019 and I2020) are conserved between mouse and
human LRRK2; all are segregating in families with disease and all are
therefore causative for disease within reasonable doubt. Since the
identiﬁcation of these mutations, additional rare variants potentially
linked with PD have been identiﬁed (Table 1). Usually the amino acid
sequence comprising the PD-linked mutation is present only in
mammals or other high-order vertebrates (annotated as ‘Conservation
medium’ in Table 1). For those variants with medium conservation,
segregation in families was usually not reported, and for the majority
of LRRK2 variants functional data on kinase or GTPase activity has not
been described. Thus, future studies that ideally involve complete
sequencing of the LRRK2 gene in both PD-patients and controls in
addition to the incorporation of standardized functional biochemical
studies will be needed to determine the potential pathogenicity of the
multitude of LRRK2 non-synonymous alterations.
As the most common LRRK2 mutation (Table 2), the frequency of
G2019S has been described in nearly all well characterized PD case/
control cohorts. The mutation is foundwith frequencies in PD patients
ranging from 40% to 0%. Interestingly, some populations display
higher proportions of cases with the common G2019S mutation in
sporadic cases or patients that report no PD in their immediate familythan those with a family background of PD. The immediate
assumption of de novo G2019S mutation is not supported by a number
of studies that demonstrate the ancient ancestry of the G2019S linked
haplotype [12–16]. The unprecedented frequency of this relatively
penetrant mutation linked with the common neurodegenerative
disorder PD perhaps reveals the inherent inaccuracy of classifying
PD patients as sporadic or non-familial and may highlight a general
underestimation of the role of genetic susceptibility in PD. Beyond the
biological implications of the role of LRRK2 in PD, the frequency of
known pathogenic mutations in PD has provided valuable insight and
will likely continue to clarify the disease in future studies. As already
Table 3
Pathology of LRRK2 mutation carriers with a clinical diagnosis of typical PD
Origin Mutation Type Pathology Cases Ref
Spain G2019S Sporadic LB, SNpc degeneration 1 [105]
G2019S Sporadic No inclusions, SNpc degeneration 1 [105]
Spain R1441R Sporadic LB, SNpc degeneration 1 [105]
UK G2019S Sporadic LB, SNpc degeneration 3 [9]
USA G2019S Sporadic LB, SNpc degeneration 6 [106,107]
No inclusions, SNpc degeneration 1
USA G2019S Familial LB, SNpc degeneration 4 [106–108]
Tauopathy, SNpc degeneration 1
USA R1441C Familial LBs, SNpc degeneration 2 [4,109]
Ub-only inclusions 1
German-
Canadian
Y1699C Familial Ub-only inclusions and
SNpc degeneration
2 [4,87,109]
UK LB, SNpc degeneration 1
Japan I2020T Familial No inclusions, SNpc degeneration 4 [11]
Italy I1371V Familial LB, SNpc degeneration 1 [110]
Table 2
Frequency of LRRK2 mutations
Origin Variant tested
(predominant)
sp = sporadic
fam = familial
Reference
North Africa G2019S sp 41% fam 37% [15,17]
Arabs G2019S sp 39% fam 36%
Ashkenazim G2019S sp 13% fam 30% [17,90]
G2019S sp 10% fam 28%
Germany Complete Seq [77,91]
(R793M) sp 2% fam 15%
G2019S sp+fam 0,5%
Portugal G2019S sp 4% fam 14% [17,92]
sp+fam 6%
Italy G2019S (6,6%) fam 10% [17,93]
R1441C (4,3%) sp 2% fam 4%
Spain R1441G/G2019S fam 5%, sp+fam 8% [17,94]
G2019S sp 3% fam 4%
United States G2019S 1–2% [18]
G2019S fam 6–7%
Russia G2019S sp 0,5% fam 5,9% [17,86]
G2019S sp 1% fam 0%
Belgium R1441C sp+fam 3,29% [82]
Chile G2019S sp 3% fam 3% [17]
Ireland G2019S spb1% fam 3% [17]
France G2019S sp+fam 2,9% [95]
Australia G2019S sp+fam 1,5% [96]
Brazil G2019S sp+fam 2% [97]
Norway G2019S sp+fam 2% [17,98]
G2019S sp 1% fam 1%
UK G2019S fam 1,8% [9,17]
G2019S sp 1% fam 2%
Sweden G2019S sp 2% fam 0% [17]
Japan G2019S spb1% fam 2% [17]
India G2019S spb1% fam 0% [17]
Canada G2019S sp+fam 0% [99,100]
Greece G2019S sp+fam 0% [101]
Poland G2019S sp+fam 0% [102]
China G2385R, risk factor sp+fam 9% [103,104]
P1628R, risk factor sp+fam 3%
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the successful discernment between benign rare variants and
pathogenic mutations.
3. Clinical and pathological aspects of LRRK2 associated disease
The clinical signs of patients with LRRK2 mutations are perhaps
surprisingly uniform for movement disorder specialists in frequent
contact with cases caused by mutation in a known PARK locus. Large
proportions of LRRK2-patients become symptomatic and seek the
treatment of neurologists upon the onset of resting tremor and
bradykinesia, similar to sporadic cases. Age at onset can vary from 30
to 90 years with amean age of onset near 60 years, although clinic and
referral bias may be responsible for an artiﬁcially lower age of onset
for LRRK2-mutation carriers. The LRRK2-associated clinical phenotype
can endure a few years to decades with no large difference to sporadic
LRRK2-negative cases when adjusted for age and sex. Statistically
signiﬁcant differences between symptomatic LRRK2-mutation carriers
and sporadic patients are therefore hard to determine. Since G2019S
carriers are by far the most abundant known LRRK2-linked cases, the
effects of this mutation are well described and tremor seems to be
more abundant with a slightly more benign disease course compared
to sporadic LRRK2-negative cases [17], with the usual caveats of clinic-
bias in mind. Further, G2019S patients have a lower risk of developing
cognitive impairment and hyposmia, needed dopamine-replacement
therapy later and presented with less frequent drug-induced
dyskinesias [17]. An important aspect is the penetrance of disease in
a particular mutation background since G2019S carriers have been
identiﬁed in apparently neurologically normal individuals including
subjects over eighty years of age [18]. Percentages of penetrance are
variable between studies with around 30% for subjects in their ﬁftiesto up to 80% in subjects older than eighty years of age [12,13,17,19].
Larger population-based studies in the future will help deﬁne the true
penetrance of LRRK2 mutations in different ethnicities and therefore
aide genetic counseling, particularly if a LRRK2-speciﬁc disease
therapy becomes available. Nevertheless, in relative comparison,
pathogenic-proven LRRK2 mutations are highly penetrant.
As rationally-designed therapeutic strategies become implemen-
ted, an important challenge to the research community lies in
developing tools for early diagnosis. Although the true risk factors
are not yet known, sequencing of patients and controls necessarily
leads to the identiﬁcation of presymptomatic family members and
carriers of mutations and risk factors. A number of imaging tools
including ultrasound, MRI and PET scans are available mostly on a
research basis to uncover early cell loss, amyloid positive aggregates,
changes in dopamine metabolism, and neuronal inﬂammation.
Studies suggest that the neurochemical changes that accompany
LRRK2-associated PD cannot be distinguished from idiopathic PD [20].
Since the ﬁeld of biomarkers in PD is yet in its infancy, one potential
approach might utilize LRRK2 function in the periphery to assess the
progression of PD. The possible presence of LRRK2 protein in
leukocytes or lymphoblastoid cells [21], if conﬁrmed with validated
antibodies, may represent a viable approach.
When LRRK2-mutations have taken their course and neuropathol-
ogists have the opportunity for analysis, the majority of brains now
described in the literature suggest LRRK2 mutations cause standard
Lewy body pathology typical for idiopathic cases (summarized in
Table 3), despite initial indications that LRRK2mutations cause highly
variable pathology. Pathology outside of the expected phenotype for
PD includes four affectedmembers of a family fromWestern-Nebraska
with the ﬁrst described R1441C mutation [4]. One case demonstrates
typical brain stem pathology, one with diffuse Lewy body pathology
and the other two with either tauopathy or pure nigral degeneration
without Lewy body formation. In addition, two subjects from the
German-Canadian family with the ﬁrst Y1699C mutation showed
degeneration of the substantia nigra, Lewy bodies and neurites were
seen in the limbic gray matter in one patient, the other had additional
degeneration of the anterior horn suggesting the coexistence of
amyloid lateral sclerosis [4]. Four patients from the Japanese kindred
with the I2020T mutation presented with pure nigral degeneration
[11]. Of note, the R1441C, the Y1699C and the I2020T are rare
mutations and can cause both clinical and pathological phenotype
well outside of the accepted PD spectrum. In contrast, the majority of
sporadic and familial G2019S patients with a diagnosis of PD
demonstrate substantia nigra degeneration and Lewy body pathology
(Table 3). As there is variation in the combination of clinical symptoms
in PD there is clear variation in end stage pathology, particularly in
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otherwise might not fulﬁll clinical criteria for typical late-onset PD.
Rather than installing LRRK2 upstream of commonly considered
pathways in rare cases, it is more convincing to associate LRRK2
mutations with the most frequently found type of pathology, namely
the accumulation of proteins into Lewy bodies in reﬁned brain regions
with dopaminergic neuronal cell loss.
4. LRRK2 expression and localization
The LRRK2 protein consists of 2527 amino acids translated from 51
exons. Initial efforts to identify splicing events or alternative exons in
mRNA derived from human brain failed to reveal common alternative
LRRK2 isoforms, although a cryptic splice site in between exons 50 and
51 results in the exclusion of 6 amino acids in a signiﬁcant proportion
of LRRK2 transcript [22]. All bioinformatically available data about
primary, secondary and higher order structure in conjunctionwith the
evolutionary tree of related proteins suggest LRRK2 as a multidomain
GTPase and kinase enzyme. LRRK1 and LRRK2 may be the only
proteins in the mammalian proteome that combine a functional
GTPase with kinase activity into one molecule. In view of upcoming
LRRK2 deﬁcient and over-expressing mouse models, LRRK1 might be
considered for potential functional overlap and compensation effects.
Several groups have focused on LRRK family expression patterns
during development and adulthood, in different cell types and
organisms. An idea of LRRK1 and LRRK2 localization patterns has
recently emerged.
First, the presence of LRRK2 mRNA was demonstrated through
Northern Blot analysis and RT-PCR in adult human brain [4,5]. In situ
hybridization followed and gave impressions about LRRK2 distribution
throughout the brain of rodents and later distribution in humans.
LRRK2, although expressed at nominal levels compared to even rare
control transcripts, can be detected in several brain regions, primarily
striatum, cortex and hippocampus [23–28]. For LRRK1, the smaller
ROCO-family member with 33 exons and 2038 amino acids, mRNA
expression is found in all areas of adult rodent brain by RT-PCR but
only very low levels can be detected by in situ hybridization [29,30]. In
contrast to LRRK2, LRRK1 is more abundant in the developing rodent
brain [30]. LRRK1 antibodies are commercially available but speciﬁcity
and ﬁnal characterization in brain tissue awaits LRRK1 deﬁcient
mouse models. LRRK2 antibodies, available from every major
commercial antibody supplier, have ﬂooded the market with reagents
with questionable speciﬁcity to LRRK2 protein, particularly mouse
LRRK2. However, LRRK2 protein is consistently detected in neurons
within the cortex, striatum, hippocampus, cerebellum, and in
dopaminergic neurons of the substantia nigra [31–33].
Initial experiments with a rabbit polyclonal antibody that detects
both mouse and human LRRK2 protein and validated through
analysis of LRRK2-null tissue presented a cytoplasmic punctate
pattern for LRRK2 protein in neurons on a light microscopy level
[33]. Multiple cell fractionation experiments demonstrated that a
signiﬁcant proportion of LRRK2 protein is membrane associated and
indeed the protein shows partial co-localization with different
markers like lyso- and mitotracker [33]. Electron microscopy further
describes LRRK2 co-localization with transport vesicles from the
Golgi to the periphery, with endosomes, synaptic vesicles and the
cytoskeleton, with localization always remaining on the cytosolic side
[33]. The distribution of LRRK2 protein in PD brains, especially
localization to Lewy body structures, varies between studies (0 to
100%) depending on the antibody [24,34–38]. The role of LRRK2 in
Lewy body formation is unknown. Although Lewy bodies are
frequently found in LRRK2-associated disease, LRRK2 itself does not
seem to be a major component.
From all tissues examined by RT-PCR, LRRK2 reaches its highest
levels in embryonic and adult kidney [39]. In situ hybridization
demonstrates a differential expression pattern between LRRK1 andLRRK2 in kidneys, as LRRK2 is predominantly in tubules of the deep
renal cortex and LRRK1 resides mostly in the renal medulla [30].
LRRK1 and LRRK2mRNA demonstrate striking overlap in expression in
several other organs, with moderate levels in developing and adult
rodent lung, heart and spleen [39]. In summary, LRRK2, as with other
PD-linked genes, is widely expressed throughout the body and in cell
types and brain regions relevant to PD. From expression patterns,
LRRK1 may play a larger role in early development whereas LRRK2
levels signiﬁcantly increase after birth.
5. LRRK2 protein function: linking PD mutations with GTPase and
kinase activity
LRRK2 is one of the largest kinases in the human kinome, with less
than ten kinases (mostly predicted kinases) derived from the PIKK
family, the Trio family and the MLCK family encoding proteins larger
than LRRK2, the majority of which remain uncharacterized on a
molecular level. While all large kinase proteins display unique
conﬁgurations of conserved protein domains, LRRK2 and the related
LRRK1 gene encode the only proteins within the mammalian genome
that include both kinase and GTPase domains, with the possible
exception of the calcium-calmodulin-dependent death-associated
protein kinase 1 (DAPK1) that contains a possible GTPase-like domain
[6]. Since the most common mutations linking LRRK2 with suscept-
ibility to PD occur within the LRRK2 kinase and GTPase domains,
attention and intense speculation immediately revolved around the
enzymatic output of LRRK2 protein prior to a functional description of
the protein.
As a highly evolutionarily conserved kinase-protein arguably
present in even some single-celled organisms with broad expression
throughout mammalian development, LRRK2 protein plausibly per-
forms dozens of functions in dozens of cells types. Perhaps the best
way to study LRRK2 as a cause and potential therapeutic target for PD
revolves around understanding how PD-associated mutant LRRK2
protein deviates from normal protein. The ﬁrst functional description
of LRRK2 protein included a comparison of the most common
mutation found in PD cases, G2019S, which localizes to the activation
loop kinase sub-domain, together with normal LRRK2 protein
sequence as found in unaffected control brain tissue [22]. While the
basic biochemical properties of wild-type and mutant protein such as
protein localization and stability are comparable, at least in transiently
transfected cell lines, the inﬂuence of the PD-linked mutations is clear
in experiments designed to assess enzymatic activity. The G2019S
mutation enhances kinase activity in autophosphorylation assays and
phosphorylation of a generic kinase substrate myelin basic protein
[22]. These ﬁndings, derived from in vitro based assays, complement
genetic studies that suggest dominant inheritance and likely gain of
function pathogenic mechanisms.
LRRK2 belongs to the tyrosine kinase-like protein family in
humans [40]. Despite the nomenclature, all described kinase proteins
within the tyrosine kinase-like family display serine and/or threonine
activity without examples of tyrosine kinase activity. Separation of
internal LRRK2 residues labeled during autophosphorylation reveal
both serine and threonine kinase activity, typical for tyrosine kinase
like proteins [41]. Although the LRRK2 kinase domain displays highest
sequence homology to the mixed-lineage kinase (MLK) subfamily of
MAPKKK protein kinases, so named due to kinase sub-domain
structure resembling both tyrosine and serine/threonine kinases,
LRRK2 differs from the consensus critical amino acids that deﬁne
mixed-lineage kinases [41]. Thus, LRRK1 and LRRK2 protein kinase
domains have unique sub-domain characteristics that clearly deline-
ate from MLKs and other MAPKKK proteins. However, like MLKs,
LRRK2 forms protein dimers in cells and dimerization is dependent on
kinase activity [42]. The LRRK2 kinase domain deviates from nearly all
protein kinases from the consensus DFG…APE activation loop motif
[43]. Since the most common LRRK2 mutation G2019S alters the
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critical to the normal regulation of kinase activity, although the serine
and threonine residues within the activation loop have not been
formally shown as autophosphorylation and possible auto-activation
sites. Thus, the high divergence of the LRRK2 kinase domain from
other well known protein kinases may provide additional opportu-
nities for speciﬁcity in therapeutic approaches but prevents compar-
isons to homologous kinases for clues to functionality.
Since the ﬁrst description of LRRK2 kinase activity, additional
studies that involve immunoprecipitation of over-expressed LRRK2
protein and assessment of autophosphorylation activity in vitro
demonstrate that pathogenic PD-linked mutations increase apparent
kinase activity [41]. Protein fragments containing the LRRK2 kinase
domain isolated from E. coli likewise demonstrate auto-phosphoryla-
tion activity and kinase activity with MBP as substrate, and the most
common LRRK2 mutation, G2019S, imparts a signiﬁcant increase in
kinase activity [44]. Notably, kinase fragments derived from the E. coli
system are guaranteed devoid of contaminating endogenous serine/
threonine and tyrosine kinases. The pathogenic LRRK2 mutation
I2020T had no signiﬁcant effect on activity versus wild-type protein,
in contrast with experiments in mammalian systems that demon-
strate either increases or decreases in activity [41,45,46]. While the
most common LRRK2 mutation G2019S faithfully reproduces
enhanced autophosphorylation, other pathogenic LRRK2 mutations
fail to reproduce enhanced activity uniformly among different
laboratories. G2019S, as opposed to other mutations, may provide
an additional autophosphorylation site in the activation loop in
addition to enhancing auto-activation that would increase autopho-
sphorylation signal even when a particular assay exceeds linearity.
Differences in kinase reaction protocol, contaminating but highly
active serine/threonine kinases in kinase reactions, lack of linearity of
autophosphorylation assays, lack of a bone ﬁde kinase substrate and
sequence differences among different LRRK2 clones and cell lines used
for recombinant protein production in different laboratories all likely
contribute to variation. Fortunately, the unresolved in vitro kinase
story does not end with the LRRK2 kinase domain since a second
enzymatic domain encoded in the LRRK2 protein, the GTPase domain,
provides an additional opportunity to understand the effects of PD-
linked LRRK2 mutations on LRRK2 protein function and LRRK2 kinase
regulation.
The ﬁrst descriptions of LRRK2 GTPase activity utilized measure-
ments of GTP-bound LRRK2 protein in cell lysates derived from
transiently transfected cells [41]. These estimations revealed that
pathogenic PD mutations near the GTPase domain increased the
proportion of LRRK2 bound to GTP, while mutations near the kinase
domain had no signiﬁcant effect on the proportion of GTP bound
LRRK2. Beyond GTP-bound LRRK2 as a surrogate measure of GTPase
activity, more in depth studies reveal that the most common LRRK2
mutations in the LRRK2 GTPase domain, R1441C and R1441G, do not
directly enhance GTP binding but convincingly decrease GTP-hydro-
lysis activity [47–49]. Structural studies demonstrate that the R1441
residue is located at the interface of two GTPase monomer structures
and that the mutation likely diminishes GTPase activity from a loss of
stabilization of the GTPase dimer [50]. Taken together, the data
suggest that the pathogenic PD mutations localized to the GTPase
domain prolong the binding to GTP compared to normal LRRK2
protein.
Concurrent with data delineating the effect of PD-associated
mutations on GTPase activity, multiple studies report that artiﬁcial
mutations within the GTPase domain that ablate GTPase activity
completely inhibit kinase activity, whereas mutations that ablate
kinase activity have no effect on GTPase activity [41,51]. Thus, the
LRRK2 protein encodes a self-regulatorymodule in the GTPase domain
that controls kinase output, where mutations that affect GTPase
activity necessarily affect kinase activity. This model explains how
mutations over 500 amino acid residues away from the kinase domainaffect kinase activity, and suggest that pathogenic LRRK2 mutations
may inﬂuence kinase function either through direct alteration of the
kinase domain, alteration of GTPase activity or potentially through
altering the interaction of the GTPase and kinase domain. The
pathogenic Y1699C mutation localized between the GTPase and
kinase domainsmay alter the structure of LRRK2 protein and inﬂuence
the contact between the GTPase and kinase domain, although this
speculation awaits structural studies with full length recombinant
LRRK2 protein.
LRRK2 encodes a protein comprised of elements usually split into
two, three or more distinct proteins to form a signal transduction
pathway. Descriptions of distant mammalian LRRK relatives in
dictyostelium likewise conﬁrm that multiple regulatory domains
function in a serial fashion to modify kinase output [52]. In the GbpC
protein, a RasGEF domain enhances GTPase activity which in turn is
required for kinase activity. Thus, a signal transduction pathway is
encoded into a single protein, with opportunities at each step for
additional regulation. Perhaps the encoded domains in LRRK2 and
related proteins represent such specialized and exact components in
controlling kinase output that splitting up the domains into separate
proteins would yield insufﬁcient control over kinase output. Regard-
less of the reason for the unique domains structure, evolution has
clearly selected for the arrangement that seemingly positions kinase
output as the critical and deﬁning feature of the proteins.
6. LRRK2-linked toxicity and function in cells
Initial efforts to understand the link between the LRRK2 protein
and neurotoxicity, namely neurodegeneration that occurs in LRRK2-
linked PD cases, focused on transient over-expression in cultured cells
as a means of delineating the basic aspects of LRRK2 associated
dysfunction. The usual caveats and questionable physiological
relevance of such approaches apply, nevertheless the most common
LRRK2 mutation G2019S results in increased markers of cellular
dysfunction versus wild-type protein expression, suggesting speciﬁ-
city and perhaps a relevant methodology to identify LRRK2-linked cell
death pathways [53]. The ﬁrst demonstration that kinase-activity is
required for cellular toxicity, at least in vitro, linked together kinase-
assay experiments with cell toxicity approaches, and reinforced
expectations for the potential therapeutic value of LRRK2 kinase
activity [36]. Likewise, expression of either GTPase dead or kinase
dead LRRK2 protein is well tolerated by cells, whereas mutant LRRK2
expression correlates with markers of toxicity [41,51].
Towards initial dissection of LRRK2-overexpression linked cell
death pathways, transfection of kinase-overactive LRRK2 causes
mitochondrial dependent apoptosis blocked by soluble caspase
inhibitors or the genetic ablation of Apaf1 [54]. However, the
mechanisms that lie in between caspase activation and LRRK2
over-expression remain elusive. The LRRK2 kinase domain contains
some sequence homology to the mixed lineage kinase sub-family of
MAPKKK proteins, and a unifying feature for MLK proteins is kinase-
dependent activation of JNK and activation of c-Jun that leads to
apoptosis when over-expressed in transfected cell lines [55]. The
MLK proteins have proven control of cell death pathways in neurons
since the MLK small molecule inhibitor CEP-1347 provides broad
neuroprotection from a variety of neurotoxic insults [56–58]. LRRK2,
in contrast to true MLK proteins, does not activate the JNK pathway
in a comparable or kinase-dependent manner when transfected into
cell lines, suggesting that LRRK2 is not a MAPKKK protein or that the
interaction in the MAP-kinase pathway is more complex than usually
observed for interacting kinase proteins [41]. Neurons undergoing
apoptosis due to LRRK2 over-expression may ultimately have
changes in p38 and JNK signaling, although potential perturbation
of the MAPK pathway does not automatically assign a role of a
MAPKKK to LRRK2 without the identiﬁcation of speciﬁc targets of
LRRK2 activity.
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the relevance of over-expressing an active kinase that may or may not
target physiological substrates or native pathways cannot be safely
assumed. Indeed, it has not been a requirement to demonstrate
endogenous LRRK2 expression in cell systems used to study LRRK2-
relevant cell death pathways, and the effects of LRRK2 expression in
dopaminergic neurons relevant to PD remain unknown, at least for the
time being since this is the current focus of many laboratories. As
opposed to the other dominant protein that can cause PD, α-
synuclein, LRRK2 expression is very low in the brain compared to
reference proteins and is by all accounts difﬁcult to detect by western
blot and immunohistochemistry [39]. The importance of LRRK2 kinase
activity towards neurodegeneration awaits validation in relevant in
vivo model systems that more closely mimic endogenous expression.
Initial in vivo toxicity experiments in transgenic Drosophila that
over-express either G2019S LRRK2 or WT LRRK2 protein under the
GAL4/UAS system demonstrate LRRK2 linked retinal degeneration
and dopaminergic degeneration, with a signiﬁcantly more severe
phenotype in G2019S versus WT LRRK2 over-expressing lines [59].
Unfortunately, the effect of human kinase-dead LRRK2 over-expres-
sion was not reported. Imai et al. provide evidence that Drosophila
LRRK (dLRRK) dysfunction in regulation of protein synthesis leads to
degeneration of dopaminergic neurons [60]. Regulation of protein
synthesis in their system is proposed to be mediated in part by
phosphorylation of the eukaryotic initiation factor 4E binding protein
(4E-BP) through dLRRK. However, dLRRK more likely represents
LRRK1 function in mammals and genetic variation in LRRK1 does not
appear to confer risk for PD [61–63]. Further, loss of dLRRK in different
genetic backgrounds of Drosophila appears to produce conﬂicting
results with respect to maintenance of dopaminergic neurons
[60,64,65]. Deletion of lrk-1 in Nematodes points towards a role of
lrk-1 in localizing synaptic vesicle proteins to synaptic terminals, a
ﬁnding that awaits conﬁrmation in mammalian model organisms to
determinewhether LRRK1 or LRRK2 or both proteins overlap with lrk-
1 function [66].
Given the relatively small tool box from which to analyze LRRK2
protein function, it is no surprise that little is known of the
endogenous role of the LRRK2 protein. The strong evolutionary
conservation of the protein and broad expression throughout
mammalian development in multiple tissues suggests a more
ubiquitous function than one conﬁned to the cell types affected in
PD. Despite the predicted importance of the gene for normal health
and cellular function, the lack of an overt or dramatic phenotype in
LRRK2 knockout mice (Saskia Biskup, Valina Dawson, Ted Dawson,
unpublished observation) is perhaps no surprise since the knockout of
the mouse α-synuclein, parkin and DJ-1 genes, all conserved proteins
likely involved in PD, result in only subtle defects. Acute knockdown of
LRRK2 via RNA interference is hindered by a lack of knowledge of the
endogenous half-life of the LRRK2 protein and by a complete lack of
commercially available LRRK2 antibodies that detect rodent LRRK2
protein. Commercial human-speciﬁc LRRK2 antibodies are relatively
more effective [39], although no described human derived cell line
expresses LRRK2 protein detectable by western blot. Possible excep-
tions like lymphoblastoid cells [21,42] await conﬁrmation in knock-
down studies with validated antibodies. Thus, outstanding issues that
hinder progress in understanding LRRK2 include effective LRRK2
antibodies and relevant cell systems and corresponding RNAi
approaches.
The ﬁrst study to assign a possible role for over-expressed LRRK2
protein demonstrates that transfection of LRRK2 kinase domain
fragments into the intact rodent CNS or full length protein into
primary cultures induces changes in neurite length and branching
morphology [67]. The reduction of neurite process morphology
caused by over-expression of LRRK2 and more-so by expression of
G2019S-LRRK2 is regarded as a marker of neurotoxicity and utilized in
several studies that estimate LRRK2-mediated cell death [41,51,53].Two unappealing scenarios might exist that introduce additional
complications when interpreting published studies: LRRK2 may
endogenously regulate process morphology through mechanisms
unrelated to the toxicity associated with LRRK2 expression, therefore
LRRK2-toxicity may be over-estimated, or LRRK2 over-expressionmay
non-speciﬁcally induce neurite morphology as a downstream con-
sequence of LRRK2 toxicity. Relevant in vivo model systems will help
resolve the controversy. However, it seems unlikely that the discovery
of a clear role for LRRK2 function in neurons will be forthcoming.
7. LRRK2 protein interactors and kinase substrates
If the kinase activity of LRRK2 links LRRK2 function with
neurodegeneration in PD, identiﬁcation and characterization of
LRRK2 kinase substrates might provide the shortest route to under-
standing the role of LRRK2 in disease. De novo identiﬁcation of
candidate kinase substrates usually presents a daunting task, ever
more difﬁcult with a large kinase proteinwith little homology to other
characterized kinase proteins. Many known kinase substrates interact
with kinase proteins in a stableway amenable to visualization through
immunoprecipitations or yeast-two hybrid analyses. In transiently
transfected cell lines, LRRK2 interacts with several components of the
cytoskeleton architecture, including vimentin, a/b-tubulin, and
clathrin [68,69]. Immunoprecipitations from brain tissue in mice
transgenic for a HA-tagged LRRK2 construct driven by the prion
promoter reveal an interaction with HSP-90 [70]. HSP-90 and
practically all isoforms have been previously described as common
protein interactors with virtually all proteins over-expressed in
mammalian cells, as identiﬁed in highly puriﬁed tandem-afﬁnity
puriﬁcations [71]. Although it is not known whether LRRK2 might
phosphorylate HSP-90 or otherwise functionally contribute to a HSP-
90 containing complex, inhibitors to HSP-90 function effectively
destabilize transfected and endogenous LRRK2 levels, suggesting that
a proportion of LRRK2 interacts with and is stabilized by the inducible
HSP-90 protein. Components of the HSP-90 complex in addition to cell
cytoskeleton components therefore seem likely targets in the hunt for
LRRK2 kinase substrates.
Apart from immunoprecipitations that require stable protein–
protein interactions, a novel approach towards identifying kinase
substrates dubbed KESTREL (kinase substrate tracking and elucida-
tion), nominated the moesin cytoskeletal protein for further study
[46]. LRRK2, in addition to several other serine threonine kinases,
phosphorylates moesin at a Thr558 residue, although moesin must be
denatured before LRRK2 can phosphorylate this site necessitating
further experiments that address whether this interaction occurs in
cells. LRRK2 may also affect the phosphorylation of 4E-BP, again
targeting sites heavily phosphorylated by other protein kinases [60].
Perhaps themost robust known LRRK2 protein interaction occurs with
LRRK2 protein itself, in the form of dimer sized structures and high
molecular weight structures [42]. The ﬁrst observation that LRRK2
might self-interact involved immunoprecipitations between LRRK2
proteins fused to two different epitopes, in this case FLAG and HA tags
[45]. Although the immunoprecipitation experiments did not formally
demonstrate the existence of a LRRK2 dimeric structure, subsequent
studies using native-PAGE and gel ﬁltration experiments demonstrate
LRRK2, similar to MLK proteins, forms dimer sized structures [42]. The
ability to self-interact might allow dissection of LRRK2 autopho-
sphorylation activity, which in the case of LRRK2, occurs in cis [42].
Future studies will determine the effect of LRRK2 quaternary structure
on function and kinase activity.
8. Conclusion
From a humble initial description in a large Japanese family to
eventually presenting as the most common known cause of PD, the
LRRK2 protein provides possibilities for successful disease models,
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potentially robust therapeutic target for disease intervention. Before
these goals can be fully realized, a number of critical issues as outlined
in this review might be considered. The delineation between benign
non-synonymous changes and pathogenic mutations is critical for an
accurate estimation of the frequency of LRRK2 mutations in PD
patients. Likewise, as the average age of the human population
continues to increase and the frequency of age-associated disease like
PD rise, genetic counselors will require accurate information particu-
larly if a LRRK2-specifc therapy should become available. Studies in
North African Arabs screened for the G2019S LRRK2 mutation
demonstrate the challenges of characterization of patient populations
where the line between familial and apparently sporadic PD is blurred,
a phenomenon that is likely not unique to this population and
underscores the difﬁculty of assigning the role of genetic susceptibility
in PD. Thus, the seemingly simple question concerning the true
frequency of LRRK2 mutations in PD even in relatively homogenous
populations may not be answered for some time. Perhaps the more
pertinent question asks what percentage of PD is caused by LRRK2
activity, and this question will not be fully answered until potent and
safe LRRK2 inhibitors become available.
The majority of LRRK2-linked PD described in the literature
demonstrates clinical and neurochemical changes consistent with
the current understanding of idiopathic late-onset PD. Most patholo-
gical descriptions of cases with LRRK2 mutations include SNpc
degeneration and Lewy body structures consistent with idiopathic
late-onset PD. Notable exceptions include familial cases in the original
families that demonstrate both clinical and pathological phenotypes
outside of the accepted spectrum for PD. These ﬁndings are not
unprecedented in monogenic PD; rather, they are expected. For
example, the Italian Contursi kindred, where the A53Tmutation in the
α-synuclein gene was ﬁrst identiﬁed, display a broad range of
pathologies that can include tau inclusions [72] and diverse clinical
manifestations that include a dramatic range of age of disease onset
from twenty to eighty-ﬁve years of age [73]. For the PD-linked genes
described on a pathologic level, namely α-synuclein, parkin, and
LRRK2, all can be considered associated with diverse pathology and
phenotypes that may not be considered within the current spectrum
of idiopathic and sporadic PD. The availability of genetic testing may
ultimately broaden the scope of pathologies and clinical manifesta-
tions presently associated with PD. However, the unprecedented
prevalence of LRRK2mutations in PD cases increases opportunities for
coincident occurrence of disease unrelated to PD, or additional
neurological disease potentially spurred by the development of
LRRK2-linked PD, both of which might be selected for in the
publication process. Thus, when taken together as a whole, the
available data suggest that LRRK2 mutations cause a clinical and
pathological phenotype that overlaps closely with the heterogeneous
PD spectrum.
Although the LRRK2 protein has been linked to PD for only a few
years, a world-wide effort to describe LRRK2 and functionally
characterize the protein has now provided a solid foundation to
move forward. LRRK2 expression in the brain is modest, although the
protein is detectable in the neurons vulnerable to degeneration in PD.
LRRK2 functions as a kinase and the most common mutation G2019S
clearly affects phosphorylation activity. The consequence of LRRK2
kinase activity, whether to enhance phosphorylation of a particular
protein substrate or perhaps alter LRRK2 function itself independent
of a tertiary kinase substrate awaits further studies and in vivo model
systems. The sheer size of the LRRK2 open-reading frame introduces
a technical challenge for nearly every biochemical application, from
the isolation of active and pure recombinant protein to the creation
of viral-vector delivery systems. However, studies that utilize
fragments of the LRRK2 protein to infer functionality of the full
length protein might be interpreted with caution, since all of the
protein domains within LRRK2 have not been fully characterized. Forexample, if the LRRK2 N-terminal repeats specify kinase substrate
interactions and this domain is not included in a particular
experiment, results that demonstrate kinase-dependent phenotype
cannot be ruled out as artifact.
The future might hold the identiﬁcation of LRRK2 kinase
substrates, some of which will be validated in vivo while others will
remain in vitro phenomena, in addition to the development of small
molecule LRRK2 inhibitors with variable levels of speciﬁcity. The ﬁeld
will rely on model systems that demonstrate a reproducible LRRK2
phenotype to test efﬁcacy of substrate interactions as well as small
molecules that might have therapeutic beneﬁt. Since LRRK2 bears
strikingly similarity both on a sequence level as well as a functional
level to proteins that have been successfully targeted in the treatment
of human disease, the prospects are as bright as ever for the
development of effective therapeutics to combat PD.
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